Brief: Novacyt H1 Revenue Down At STG 3.3 Mln VS STG 16.5 Mln Year Ago

Novacyt SA

28/09/2023 07:07

Sept 28 (Reuters) - Novacyt SA  ALNOV.PA  published H1
results on Thursday:
    * H1 REVENUE 3.3 MILLION STG VERSUS 16.5 MILLION STG YEAR
AGO
    * H1 EBITDA LOSS EXCLUDING ITEMS 5.4 MILLION STG VERSUS 7.1
MILLION STG LOSS YEAR AGO
    * H1 LOSS PER SHARE 12.0 PENCE VERSUS 12.0 PENCE LOSS YEAR
AGO
    * CASH POSITION AT 30 JUNE 2023 WAS £81.7M (FY 2022: £87.0M)
AND
COMPANY REMAINS DEBT FREE
    * ON TRACK TO COMPLETE IVDR CLINICAL TRIAL FOR WINTER
RESPIRATORY
PANEL, GENESIG™ REAL-TIME PCR SARS-COV-2 WINTERPLEX, IN EARLY
2024

Source text for Eikon:  ID:nRSb9027Na 
Further company coverage:  ALNOV.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))